GlassScriptPhysician profile
Robert William Wong
NPI 1275699274
$113,426.78
in general payments reported to CMS, 2019-2025
36 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,707 · 2020: $550 · 2021: $568 · 2022: $58K · 2023: $49K · 2024: $2,122 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Food and Beverage: $4,702 · Grant: $500 · Entertainment: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,700.00 |
| Food and Beverage | $4,702.23 |
| Grant | $500.15 |
| Entertainment | $144.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $97,590.00 | 2022-2023 | Hillrom - Retinavue 700 Imager, Hillrom - Retinavue Network |
| US Retina LLC | $4,331.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $3,370.37 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $1,050.88 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $1,002.10 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $782.07 | 2022-2025 | Syfovre |
| Abbvie INC. | $699.06 | 2024-2025 | |
| Alcon Vision LLC | $626.43 | 2019-2025 | Constellation |
| Regeneron Pharmaceuticals, INC. | $470.26 | 2022-2025 | Eylea Hd |
| Mallinckrodt Hospital Products INC. | $400.47 | 2020-2025 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $381.28 | 2019-2022 | |
| Astellas Pharma US INC | $292.10 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $281.56 | 2019-2025 | |
| Genentech, INC. | $265.11 | 2019-2025 | Vabysmo, Susvimo |
| Bausch & Lomb Americas INC. | $195.45 | 2023-2025 | Xipere, Visudyne |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $188.30 | 2023 | |
| Carl Zeiss Meditec, INC. | $175.63 | 2020 | |
| Alimera Sciences, INC. | $155.17 | 2022-2024 | Yutiq, Iluvien |
| Optos, INC. | $144.43 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Ani Pharmaceuticals, INC. | $134.50 | 2023-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Allergan, INC. | $132.75 | 2019 | |
| Astellas Pharma Global Development | $130.87 | 2024 | Izervay |
| Rxsight INC | $127.22 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Amgen INC. | $107.67 | 2024 | Tepezza |
| Optovue, INC. | $100.00 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.38 | 2021 | |
| Ocular Therapeutix, INC. | $55.21 | 2024 | Dextenza |
| Dutch Ophthalmic, USA | $19.55 | 2022 | |
| Horizon Therapeutics Plc | $14.91 | 2023 | Tepezza |
| Biogen, INC. | $12.87 | 2023 | |
| Travere Therapeutics, INC. | $9.80 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,285.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.